***Background.*** Colonized long-term care facility (LTCF) residents are a potential source of transmission of healthcare-associated pathogens during hospital admissions. Although asymptomatic carriage of toxin-producing strains of *Clostridium difficile* is common in LTCFs, it is not known if asymptomatic carriers contribute significantly to transmission in hospitals.

***Methods.*** During a 6-month period, *C. difficile* isolates from *C. difficile* infection (CDI) cases in a VA hospital and from 38 asymptomatic carriers identified through active surveillance in the affiliated LTCF were typed by restriction endonuclease analysis (REA). Ward exposures were defined as the presence of an incident CDI case on the ward concurrently with or within 30 days after discharge of another incident case or an asymptomatic carrier. Linkage was defined as both exposure and an identical REA group or type. Asymptomatic carriers were deemed as shedders if they had a relatively high burden of *C. difficile* (defined as \>26 colonies/perirectal swab) and positive skin and/or environmental cultures.

***Results.*** Of 25 hospital-onset CDI cases, 9 (36%) were linked to asymptomatic carriers, 10 (40%) were linked to other CDI cases, and 3 (12%) had concurrent exposure to carriers and to other CDI cases. Of the 38 carriers, 24 (63%) had skin and/or environmental shedding and 20 (53%) were transferred to the hospital one or more times (range, 1 to 6 transfers). All potential transmissions from asymptomatic carriers were linked to 5 shedders, including one carrier who was linked to 4 CDI cases during 3 hospital admissions. The most common strains transmitted by carriers were the BI epidemic strain and DQ, a novel binary toxin-positive strain.

***Conclusion.*** LTCF residents asymptomatically colonized with *C. difficile* may contribute significantly to transmission during hospital admissions. A subset of carriers with increased burden of *C. difficile* and shedding of spores onto skin and/or into the environment may present a particularly high risk for transmission.
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